As we expected, B-ALL patients with low-risk characteristics (Fig. 4B), with MRD levels exceeding 1% (Fig. 4C) and with ETV6/RUNX1 fusion (Fig. 4D), were predominantly occupied by smaller TCR clonotype groups. This evidence concerns the gene RUNX1 and acute lymphoblastic leukemia.